Management of invasive fungal infections: a role for polyenes

Pranatharthi Chandrasekar*

Wayne State University School of Medicine, Detroit, MI, USA

*Harper University Hospital, 390 John R, S Hudson, Detroit, MI 48201, USA. Tel: +1-313-745-9649; Fax: +1-313-993-0302; E-mail: pchandrasekar@med.wayne.edu

The spectrum of invasive fungal infections (IFIs) continues to evolve with the emergence of rare and resistant fungal pathogens. Clinicians are faced with difficult diagnostic and treatment challenges in the management of immunocompromised patients at high risk of developing IFIs. Early and appropriate antifungal therapy is essential for a successful outcome when treating invasive mycoses. The armamentarium of antifungal drugs continues to grow; the three main classes of commonly administered drugs are the polyenes, azoles and echinocandins. The newer triazoles and the echinocandins have changed primary treatment options for some fungal infections, such as aspergillosis and candidiasis. However, despite their toxic potential, the oldest antifungal drugs, polyenes, remain useful in the treatment of IFIs because of their broad-spectrum activity, low rates of resistance and established clinical record, particularly in immunocompromised patients with breakthrough fungal infections. This review highlights important issues in the treatment of IFIs for consideration by clinicians.

Keywords: IFIs, immunocompromised hosts, antifungal therapy

Introduction

Invasive fungal infections (IFIs) are a major cause of morbidity and mortality in immunocompromised patients.1 The increasing incidence and changing epidemiology of IFIs pose a significant diagnostic and therapeutic challenge in this patient population.2,3 Although Candida albicans, Cryptococcus neoformans and Aspergillus fumigatus continue to be the most common causes of opportunistic IFIs,4 there are increasing reports of infections with rare/emerging pathogens, including non-albicans Candida species, opportunistic yeast-like fungi (e.g. Trichosporon and Rhodotorula spp.), non-fumigatus Aspergillus spp., Zygomycetes and hyaline moulds (e.g. Fusarium and Scedosporium spp.).4–6 Diagnosing these rare and emerging IFIs is more difficult than diagnosing common IFIs,5 and many of these fungi are considered to be more resistant to standard antifungal drugs.4,7

Three main classes of antifungal drugs are available for treating IFIs: polyenes; azoles; and echinocandins. The most commonly used drugs target components of either the fungal cell wall or membrane. With the changing spectrum of pathogens and growing concern over resistance to newer antifungal agents (e.g. azoles and echinocandins),8–10 a reassessment of the utility of older, broad-spectrum antifungal agents (e.g. polyenes) may be warranted. This review will provide a brief overview of the spectrum of available antifungal agents, highlight key issues associated with drugs used in the management of fungal infections and summarize current treatment guidelines/options. In addition, two case studies are presented to demonstrate the use of polyenes in patients with breakthrough infections.

Search strategy and selection criteria

Relevant articles were identified by searches of PubMed (1966–2010) using the following search terms: invasive fungal infections; immunocompromised hosts; polyenes; antifungal therapy; resistance; breakthrough fungal infections; azoles; and echinocandins. Search terms were entered either individually or in various combinations. Additional articles were identified by cross-referencing citations from articles identified through PubMed. Only English language reports were reviewed in detail and articles covering relevant topics were included in this manuscript.

Antifungal drugs

Polyenes, azoles and echinocandins have distinct mechanisms of action, and target different sites of the fungal cell wall or membrane (Figure 1).1,2,11–14 In addition to the three main drug classes, a number of other agents are being added to the antifungal armamentarium, including allylamines, flucytosine, griseofulvin, sordarins, nikkomycins, ciclopiroxolamine, 1,3-dithian-2-yldienes and other pyrrole derivatives.2 Flucytosine, which is prescribed in combination with amphotericin B, will be discussed briefly.

Polynes

Introduced in the 1950s, the polyenes represent the oldest family of antifungal drugs.1,2 Many polyenes have been isolated...
from Streptomyces spp.; however, only amphotericin B, lipid formulations of amphotericin B (amphotericin B lipid complex (ABLC), liposomal amphotericin B (L-AMB) and amphotericin B colloidal dispersion) and topical nystatin remain in widespread clinical use.\(^2,14–16\) The biological activity of amphotericin B is mediated through its binding to ergosterol, an essential component of the fungal cytoplasmic membrane.\(^2\) Binding results in the formation of aqueous and non-aqueous channels that increase membrane permeability. Cellular components, including proteins and monovalent and divalent cations, flow through these pores, which leads to the loss of membrane potential and, ultimately, cell death.\(^1–2,12\)

### Azoles

Itraconazole, fluconazole and the newer triazoles, voriconazole and posaconazole, are the most commonly used azoles in clinical practice.\(^2\) The antifungal activity of azoles, like polyenes, is mediated by targeting the fungal cell membrane. Unlike the polyenes, however, azoles interrupt the ergosterol biosynthetic pathway by targeting the cytochrome P (CYP) 450 enzymatic pathway.\(^1,17\) Ergosterol depletion leads to the accumulation of toxic sterols on the fungal surface, which causes fungal cellular disruption, and inhibits fungal growth and replication.\(^3\)

### Echinocandins

The echinocandins represent the newest class of antifungal agents developed, and include caspofungin, micafungin and anidulafungin.\(^1,18,19\) Echinocandins interfere with fungal cell wall synthesis through the non-competitive inhibition of \(\beta\)-1,3-glucan synthesis. \(\beta\)-1,3-Glucan is an integral component of the fungal cell wall.\(^19,20\) Inhibition of \(\beta\)-1,3-glucan synthesis results in weakening of the cell wall, a breakdown of cellular integrity and, ultimately, cell lysis.\(^1\) The lack of a cell wall in mammalian cells makes this an attractive and specific target for antifungal activity.\(^5\)

### 5-Flucytosine

Flucytosine is unique in its mechanism of action among antifungal agents; it is the only available antimetabolite.\(^2\) Some fungal pathogens possess enzymes required to internalize and convert flucytosine to 5-fluorouracil. The incorporation of 5-fluorouracil into a growing RNA molecule causes premature chain termination. In addition, 5-fluorouracil can act on thymidylate synthase to inhibit DNA synthesis. The inhibition of DNA and RNA synthesis subsequently leads to cell death.\(^7\) Many filamentous fungi lack enzymes necessary for the internalization and conversion of flucytosine; therefore, the fungicidal activity of 5-flucytosine is limited to yeasts, namely Candida species and \(C.\) neoformans.\(^2,21\)

### Spectrum of activity against fungal pathogens

Antifungal agents differ in their spectrum of activity against fungal species (Figure 2).\(^2,22–24\) Polyenes exhibit the broadest range of activity. They are active against most Candida species and \(C.\) neoformans as well as many moulds, including Aspergillus spp., Fusarium spp. and Zygomyces.\(^11\) Polyenes are also active against endemic mycoses, but have limited activity against Scedosporium spp.\(^11,14,25\) In addition to their broad spectrum of antifungal activity, a general advantage of polyene therapy is their long history of usage with a low incidence of resistance.\(^3\)

Azoles vary in their level and complement of activity against fungal species. In general, azoles are effective against Candida, Cryptococcus and Aspergillus spp.\(^1,26,27\) However, activity against Zygomyces, Fusarium and Scedosporium spp. has been mixed.\(^11\) Recent data suggest that voriconazole has variable activity against Fusarium spp. and may be effective against Scedosporium spp.\(^18,29\) In contrast, posaconazole is effective against Zygomyces and may be particularly useful as step-down therapy after initial treatment with amphotericin B.\(^30–32\) Azoles have fungistatic activity against Candida and fungicidal activity against Aspergillus.

---

![Figure 1. Targets of antifungal drugs in the fungal cell wall, membrane and nucleus. ABCD, amphotericin B colloidal dispersion.](image-url)

### Table: Antifungal Agents

<table>
<thead>
<tr>
<th>Class</th>
<th>Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Azoles</strong></td>
<td>Fluconazole, Ketoconazole, Itraconazole, Voriconazole, Posaconazole</td>
</tr>
<tr>
<td><strong>Echinocandins</strong></td>
<td>Caspofungin, Micafungin, Anidulafungin</td>
</tr>
<tr>
<td><strong>Polyenes</strong></td>
<td>Amphotericin B, Abelcet (ABLC), AmBisome (L-AMB), Amphotec (ABCD)</td>
</tr>
</tbody>
</table>

---

**Figure 1.** Targets of antifungal drugs in the fungal cell wall, membrane and nucleus. ABCD, amphotericin B colloidal dispersion.
Echinocandins have a broad spectrum of fungicidal activity against most Candida and fungicidal action against the actively growing tips of Aspergillus spp. Caspofungin is the only echinocandin approved for the treatment of refractory aspergillosis. Echinocandins are not generally active against other fungi that cause invasive mycoses, such as Cryptococcus spp., Fusarium spp., Scedosporium spp. or Zygomycetes, and are not recommended as treatment options for these fungal pathogens.

Flucytosine is primarily active against Candida spp., C. neoformans and certain mould species. Reported primary resistance to flucytosine monotherapy among Candida and Cryptococcus isolates remains very low (<2%). However, the development of secondary resistance has prompted the use of flucytosine in combination with amphotericin B or fluconazole.

Current treatment recommendations/options

An early diagnosis and prompt initiation of appropriate antifungal therapy is important for optimal outcome. Effective treatment may involve the surgical debridement of infected tissue and, importantly, immune restoration. Empirical antifungal treatment is often initiated when a microbiological diagnosis of fungal pathogens is unavailable in high-risk patients presenting with clinical signs and symptoms. Polyenes have a valuable role in empirical therapy because of their broad spectrum of fungicidal activity against yeasts and moulds, and a low incidence of resistance. Lipid formulations of amphotericin B have lower toxicity than conventional amphotericin B and represent an effective alternative for certain patients.

Despite their broad range of activity against Candida spp., the role of polyene therapy has markedly diminished with the availability of newer azoles and echinocandins. In the recently published Infectious Diseases Society of America (IDSA) guidelines for the management of candidiasis in non-neutropenic patients, fluconazole or an echinocandin is the preferred option for first-line therapy. In the neutropenic patient, initial therapy with echinocandins is suggested until the Candida sp. is identified. For infections caused by Candida glabrata, the IDSA recommends echinocandin therapy, while fluconazole therapy is advised for infections caused by C. albicans, Candida tropicalis and Candida parapsilosis. Polyenes are recommended as alternative therapy in cases of intolerance or limited availability of other antifungal agents. The recommended duration of therapy for candidiasis is 2 weeks following documented clearance and symptom resolution.

<table>
<thead>
<tr>
<th>Fungal species</th>
<th>Yeasts</th>
<th>Moulds</th>
<th>Antifungal agent</th>
</tr>
</thead>
<tbody>
<tr>
<td>C. albicans</td>
<td></td>
<td></td>
<td>AMB FLC ITC VRC POS CAS MFN ANI</td>
</tr>
<tr>
<td>C. tropicalis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. parapsilosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. krusei</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. glabrata</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. neoformans</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. fumigatus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zygomycetes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fusarium spp.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scedosporium spp.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Clinical utility of polyenes

<table>
<thead>
<tr>
<th>Clinical indication</th>
<th>Polylene therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cryptococcosis</td>
<td>in cases of meningitis or dissemination</td>
</tr>
<tr>
<td>Mucormycosis</td>
<td>high dose (≥5 mg/kg/day of lipid-form amphotericin B)</td>
</tr>
<tr>
<td>Invasive aspergillosis: voriconazole intolerance or failure</td>
<td>polyene alone or in combination with echinocandins</td>
</tr>
<tr>
<td>Suspected invasive mould (mucormycosis ± aspergillosis) infection</td>
<td>empirical therapy</td>
</tr>
<tr>
<td>Fusariosis</td>
<td>for species not susceptible to voriconazole</td>
</tr>
<tr>
<td>Histoplasmosis, blastomycosis, coccidioidomycosis, sporotrichosis, penicilliosis</td>
<td>in cases of severe infection</td>
</tr>
</tbody>
</table>

Figure 2. Range of activity of antifungal drugs. AMB, amphotericin B (including lipid formulations of amphotericin B); FLC, fluconazole; ITC, itraconazole; VRC, voriconazole; POS, posaconazole; CAS, caspofungin; MFN, micafungin; ANI, anidulafungin.
Polycenes remain a part of the recommended initial frontline treatment regimen for patients with cryptococcosis. The National Institute of Allergy and Infectious Diseases Mycoses Study Group established specific guidelines that are dependent upon the anatomical site of involvement (e.g. CNS versus non-CNS involvement) and the patient’s immune status (e.g. with or without HIV infection). For HIV-negative patients with CNS involvement, combined treatment with amphotericin B and flucytosine for 2 weeks, followed by 8–10 weeks of consolidation with fluconazole, is recommended. Consolidation therapy with fluconazole may be extended for up to 12 months if necessary, depending on the patient’s clinical status. The recently published guidelines for the management of cryptococcal disease recommend ≥4 weeks of induction therapy with amphotericin B plus flucytosine in non-HIV-infected, non-transplant hosts with CNS involvement. The new guidelines also advise substitution with ABLC or L-AMB if patients are intolerant of conventional amphotericin B. In HIV-negative patients with pulmonary disease, azole monotherapy with fluconazole is recommended as first-line treatment; itraconazole or amphotericin B are acceptable alternatives. All formulations of amphotericin B are recommended for severe pulmonary cryptococcal disease. The preferred treatment for patients with HIV and cryptococcal meningitis is amphotericin B and flucytosine for 2–10 weeks, followed by fluconazole maintenance therapy. The use of lipid formulations of amphotericin B is dictated by the patient’s underlying renal function; lipid formulations of amphotericin B may be substituted in patients with, or those predisposed to, renal dysfunction.

In a direct head-to-head comparison of L-AMB or amphotericin B as induction therapy for acute cryptococcal meningitis in HIV-positive patients, the efficacy of the liposomal formulation was not superior to that of amphotericin B, but the former had significantly less toxicity.

Voriconazole has replaced amphotericin B as the recommended therapy for treatment of invasive aspergillosis. Reasonable management options for refractory aspergillosis include dosage adjustments, a change in drug class or combination antifungal therapy. Lipid formulations of amphotericin B may be used as alternatives in patients who are intolerant of voriconazole or who have refractory aspergillosis. Recently published IDSA guidelines acknowledge the fact that significant knowledge gaps remain with respect to the best treatment regimen for refractory aspergillosis. Managing breakthrough IFIs remains difficult and depends upon good clinical judgement.

There are no established guidelines for the treatment of rare and emerging mould infections. Zygomycetes infections are resistant to echinocandins and azoles, including voriconazole. The incidence of breakthrough infections caused by Zygomycetes in patients receiving therapy for invasive aspergillosis is on the rise. Amphotericin B formulations and posaconazole have demonstrated activity against mucormycosis. Lipid forms of amphotericin B are utilized as first-line therapy for mucormycosis, often supplemented by surgical debridement and polycene therapy is often switched to oral posaconazole after clinical stabilization. The duration of therapy remains unclear and is usually based upon clinical and radiological status, and correction of the underlying immune deficit.

Conventional amphotericin B is the drug of choice for induction therapy of moderate to severe cases of histoplasmosis, while itraconazole and fluconazole are effective for induction and consolidation therapy in milder cases of histoplasmosis. In a study conducted in patients with AIDS, L-AMB demonstrated lower toxicity, superior efficacy and improved survival, suggesting that it may be an attractive alternative to conventional amphotericin B in the treatment of moderate to severe disseminated histoplasmosis.

Fusariosis is an uncommon fungal infection usually diagnosed in immunocompromised patients with prolonged neutropenia or after corticosteroid use for graft-versus-host disease (GVHD) in stem cell transplant patients. Some Fusarium spp. are susceptible to polycene therapy, but resistant to voriconazole, while others may only be susceptible to voriconazole. In the Collaborative Exchange of Antifungal Research database, ABLC was administered as first-line or second-line therapy. 46% of evaluable patients with fusariosis (n=26) were cured or improved and 12% were stabilized.

First-line therapy for scedosporiosis has not yet been firmly established. Scedosporium apiospermum infections may generally be treated with voriconazole; polycenes are ineffective against this fungal species. In vitro studies suggest that there may be synergistic interaction between polycenes and echinocandins (micafungin) against Scedosporium spp. Evidence also suggests that combination therapy with voriconazole and terbinafine may be effective against Scedosporium prolificans infections.

### Issues with azole and echinocandin therapy

Resistance to antifungal drugs has become an important clinical problem with azoles. Molecular mechanisms for resistance are poorly understood. Recognized mechanisms for azole resistance include reduced intracellular accumulation of drugs (due to either decreased uptake or increased efflux), altered ergosterol biosynthetic enzymes, amplification of genes encoding target enzymes and development of pathways bypassing target enzymes. Resistance to azoles in A. fumigatus is being recognized as a potential clinical problem. Resistance becomes relevant in the clinical setting as a result of the replacement of an initially susceptible species by intrinsically resistant pathogens or selection of a more resistant strain of the same species.

Azoles may serve as inhibitors of or substrates for several CYP 450 isoenzymes to a varied extent, which may contribute to significant drug interactions (Tables 2 and 3). In addition, serum levels of azoles (voriconazole, in particular) may need to be monitored to avoid toxicities and ensure efficacy. The need for monitoring is underscored by the unpredictable relationship between dosing and plasma concentrations for several of the azoles. While the need for serum concentration monitoring is gaining clinical attention (particularly voriconazole and posaconazole), few laboratories currently perform these drug assays on a routine basis.

One drawback of an echinocandin is its limited spectrum of activity. It has fungicidal effects on Candida spp., but static activity against Aspergillus. Although resistance to Candida spp. is rare, a few case reports suggest that resistance to echinocandins may be seen in Candida spp., including C. albicans, C. glabrata, Candida krusei and C. parapsilosis.
The most significant side effect associated with conventional amphotericin B usage is renal toxicity.\textsuperscript{1,81} Lipid formulations of amphotericin B are less nephrotoxic than conventional amphotericin and may be administered safely.\textsuperscript{1,3,82} While acute liver failure is rarely reported in patients receiving polyene therapy, hepatotoxicity is a concern; an increased incidence of hepatocellular and cholestatic injury, as well as increased alanine transaminase levels, are associated with fewer infusion-related reactions than ABLC. Whether the two lipid forms of amphotericin B have varying nephrotoxicity potential remains unclear.\textsuperscript{81,84–89}

### Case studies of infection breakthrough: value of polyenes

Prolonged use of antifungal agents may increase the risk of emergence of ‘resistant’ organisms in immunocompromised hosts. For example, Zygomycetes and A. ustus infections have emerged in stem cell transplant recipients receiving voriconazole.\textsuperscript{90,91} Breakthrough invasive aspergillosis has also been reported in haematopoietic stem cell transplant recipients receiving caspofungin.\textsuperscript{92} The following case studies illustrate instances in which patients receiving azole prophylaxis/therapy developed breakthrough infections that responded to polyene therapy.

#### Case study I

A patient with diabetes mellitus and acute myelogenous leukaemia underwent HLA-matched, sibling-donor peripheral blood stem cell transplantation. A significant complication included acute GVHD of the skin and liver, which responded to therapy with methylprednisolone along with tacrolimus.

Two years later, a flare up of GVHD of the skin occurred and lung GVHD (bronchiolitis obliterans) was diagnosed. The dose of tacrolimus was increased and corticosteroid therapy (40 mg methylprednisolone twice daily) was reinstituted. Antifungal prophylaxis with oral posaconazole (200 mg three times daily) was initiated. Six weeks later, with a tapering dose of methylprednisolone, the patient presented with complaints of dry cough, shortness of breath, left-sided pleuritic chest pain, low-grade fever and fatigue of 1 week duration. On examination, the patient was alert, febrile and oriented, and in mild respiratory distress. Air entry was markedly diminished over the mid and lower zones of the left lung; no pleural rub or rales was detected. Laboratory values were: haemoglobin, 11.2 g/dL; white blood cell count, 8000/mm\(^3\); platelet count, 169,000/mm\(^3\); serum creatinine, 1 mg/dL; and serum glucose, 111%. Liver function tests were normal; the serum aspergillus galactomannan level was 0.08 (normal <0.5). Chest X-ray showed two well-rounded, thick-walled cavities with air fluid levels in the left mid and lower lung fields (Figure 3a). A chest CT scan revealed a round cavity-like lesion with fluid and an air pocket in the left lower lung (Figure 3b). A CT-guided transthoracic lung biopsy was negative on culture for bacteria, viruses and fungi; the histopathology revealed acute and chronic inflammatory changes, and fungal hyphal elements suspicious for Mucor.

Polynes have a broad spectrum of activity, with few reports of resistance. However, limited activity against Aspergillus terreus, Aspergillus ustus and Scedosporium spp. has to be taken into consideration with polyene therapy.\textsuperscript{25,26}

### Issues related to treatment with polyenes

Against C. parapsilosis, echinocandins have intrinsically low activity in vitro. Echinocandins are safe, with fewer drug interactions compared with polyenes and azoles.\textsuperscript{52} In contrast to azoles, drug–drug interactions are not a concern for the echinocandins.\textsuperscript{80}

#### Table 2. Interactions of azoles with the cytochrome system\textsuperscript{19,22}

<table>
<thead>
<tr>
<th>Azole</th>
<th>Cytochrome P450 interactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluconazole</td>
<td>inhibitor 2C19+, 2C9++, 3A4+++</td>
</tr>
<tr>
<td>Itraconazole</td>
<td>inhibitor 2C9+, 3A4+++</td>
</tr>
<tr>
<td>Voriconazole</td>
<td>inhibitor 2C19++, 2C9++, 3A4++</td>
</tr>
<tr>
<td>Posaconazole</td>
<td>inhibitor 3A4+++</td>
</tr>
</tbody>
</table>

Degree of activity: +, minimal effect; ++, moderate effect; and ++++, strong effect.

#### Table 3. Major drug–drug interaction with azoles\textsuperscript{19,52}

<table>
<thead>
<tr>
<th>Azole</th>
<th>Increase concentration of non-antifungal drug</th>
<th>Decrease concentration of antifungal drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluconazole</td>
<td>phenytoin, warfarin, rifamycins</td>
<td>phenytoin, carbamazepine</td>
</tr>
<tr>
<td>Itraconazole</td>
<td>calcineurin inhibitors, sirolimus, statins, phenytoin, warfarin, rifamycins</td>
<td>phenytoin, carbamazepine</td>
</tr>
<tr>
<td>Voriconazole</td>
<td>calcineurin inhibitors, sirolimus, statins, phenytoin, warfarin, rifamycins</td>
<td>phenytoin, carbamazepine, efavirenz</td>
</tr>
<tr>
<td>Posaconazole</td>
<td>calcineurin inhibitors, sirolimus, phenytoin, warfarin, rifamycins</td>
<td>phenytoin, rifabutin</td>
</tr>
</tbody>
</table>

\textsuperscript{a}Contraindicated.
Mucor were seen within the granuloma (Figure 3c). Serum creatinine levels gradually rose to 1.6 mg/dL and, so, after 2 weeks of 7.5 mg/kg/day ABLC, the dose was decreased to 5 mg/kg/day. Clinical improvement was noted. After 2 months of therapy with ABLC, treatment was changed to 400 mg oral posaconazole twice daily. At 1 year follow-up, the patient was doing well.

In this patient, breakthrough pulmonary mucormycosis occurred, despite prophylaxis with posaconazole. After surgical resection and several weeks of intravenous ABLC, step-down therapy with oral posaconazole was instituted with successful outcome.

**Case study II**

A patient with a history of myelodysplastic syndrome underwent an HLA-matched, sibling-donor allogeneic hematopoietic stem cell transplantation. The conditioning regimen consisted of busulfan and fludarabine; thymoglobulin was administered as prophylaxis against GVHD. Both the donor and recipient were seronegative for cytomegalovirus. The patient developed GVHD of the gastrointestinal tract, for which therapy with tacrolimus and methylprednisolone was administered. Concomitantly, prophylaxis with 200 mg oral voriconazole twice daily was initiated. A random level of voriconazole obtained ~1 month later was 0.8 mg/L.

Four months later, the patient was admitted with fever, cough and shortness of breath. Physical examination showed a temperature of 101°F, a pulse of 100/min, respiration of 18 breaths/min, blood pressure of 100/80 mm Hg and oxygen saturation of 96% on 2 L of oxygen. Chest X-ray and CT scan revealed a consolidated mass in the left upper lobe of the lung. Bronchoalveolar lavage (BAL) did not yield any positive results. Serum aspergillus galactomannan and BAL fluid galactomannan were negative; however, serum β-D-glucan was >500 pg/mL. A wedge biopsy of the left lung was performed; acute and chronic inflammatory changes were noted on histopathological examination of the lung, but no aetiological diagnosis was established. Specific stains and cultures of the lung specimen for bacteria, viruses and fungi were negative. Based on the clinical presentation, serum β-D-glucan level and biopsy findings, breakthrough invasive filamentous fungal infection was suspected. Prophylaxis with voriconazole was stopped and therapy with ABLC (5 mg/kg/day) was initiated. The patient tolerated the treatment with ABLC well, with good clinical and radiological improvement. After 3 weeks of antifungal therapy, the serum β-D-glucan test was negative. No renal toxicity was observed during the 2 month period of treatment with ABLC. At the 3 month follow-up after discontinuation of antifungal therapy, the patient appeared to be doing well clinically, with good radiological improvement of the left lung lesion.

This patient had probable breakthrough IFI, despite prophylaxis with voriconazole. Failure of histopathological examination and culture of tissue to reveal a fungal pathogen in the setting of an IFI is not rare. Successful therapy was achieved with intravenous ABLC.

**Discussion and conclusions**

The spectrum of IFIs among immunosuppressed patients continues to evolve with the increasing incidence of rare and emerging pathogens, and poses a significant challenge in the diagnosis and treatment of these patients. Early and appropriate antifungal therapy is important for successful outcomes. Polyenes are the oldest antifungal drugs, and lipid formulations of amphotericin B have reduced nephrotoxicity and less infusion-related reactions associated with conventional amphotericin B.
Azoles, especially newer triazoles, have activity against a broad spectrum of fungal pathogens and have replaced polyenes as initial therapy for aspergillosis. However, toxicities and drug interactions are common occurrences with newer triazoles, and clinicians should carefully monitor patients for therapeutically drug levels and toxicities. Candida resistance to azoles is of concern and Aspergillus resistance has been reported. Echinocandins have a good safety profile and are highly active against Candida infections; they are now recommended as the primary treatment option for candidiasis. However, they do not have activity against Cryptococcus, Fusarium and Scedosporium spp. or Zygomycetes.

Despite their potential toxicity, polyenes remain useful in the treatment of IFIs because of their long track record, broad spectrum of activity and low rates of documented resistance. With prolonged use of antifungal drugs, particularly azoles and echinocandins, in prophylactic and empirical settings in immunocompromised individuals, clinicians should anticipate breakthrough infections. Whenever possible, accurate identification of the infecting organism is critical for the optimal management of breakthrough IFIs.

**Transparency declarations**

None to declare.

**References**

19. Zaas AK. In the modern day, what are the potential advantages of echinocandins over azoles and polyenes in drug interactions? *J Inv Fungal Infect* 2007; 1: 133–43.
31. Sun QN, Fothergill AW, McCarthy DI et al. In vitro activities of posaconazole, amphotericin B, and fluconazole against 37 clinical


33 Denning DW, Marr KA, Lau WM et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53: 337–49.


